Oral anticoagulation cost in primary antiphospholipid syndrome: comparison between warfarin and hypothetical rivaroxaban

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
Antonio CiampaPaul R J Ames

Abstract

: The objective of the study is to perform a cost comparison of 1 year of oral anticoagulation management with warfarin vs. hypothetical rivaroxaban (RRX) in thrombotic primary antiphospholipid syndrome. Longitudinal study on 20 primary antiphospholipid syndrome patients followed-up for 1 year after anticoagulation stabilisation with warfarin: a dedicated software calculated number of clinic visits, time in therapeutic range and warfarin consumption for each patient; for RRX, we considered a visit every 3 months (baseline done in hospital before attending anticoagulant clinic); knowing the cost of both anticoagulants, the laboratory cost and the human cost we calculated and compared the yearly expenditure. Average time in therapeutic international normalized ratio range was 69 ± 11%: warfarin management required a total of 375 of visits compared with the 60 for RRX; the yearly cost of RRX was superior to that of warfarin (12 012 vs. 446.4 euros, P < 0.0001), and in spite of lower laboratory (738 vs. 1853 euros, P < 0.0001) and human costs (774.6 vs. 4841 euros), RRX thromboprophylaxis still yielded a hefty bill (13 525 vs. 7140 euros, P < 0.0001). Switching from warfarin to RRX will be 48% more expensive to our Healthcare Autho...Continue Reading

References

Jan 28, 2014·Annals of the Rheumatic Diseases·R CerveraUNKNOWN Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies)
Dec 3, 2014·Revista brasileira de reumatologia·Felipe Freire da Silva, Jozélio Freire de Carvalho
Feb 13, 2016·Thrombosis and Haemostasis·Paul R J AmesVincenzo Brancaccio
Jun 5, 2016·Thrombosis Research·Claudia DimatteoMaurizio Margaglione
Oct 30, 2016·Journal of the American Heart Association·Jay M MargolisJeff Schein

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.